ATC Group: J06BB09 Cytomegalovirus immunoglobulin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BB09 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BB Specific immunoglobulins
5 J06BB09 Cytomegalovirus immunoglobulin

Active ingredients in J06BB09

Active Ingredient

Cytomegalovirus immunoglobulin is used as a CMV-specific polyclonal immunoglobulin preparation that binds to CMV surface antigens thereby neutralizing the potential of CMV from entering host cells and presenting the CMV particle for phagocytosis. Furthermore, cytomegalovirus immunoglobulin can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses.

Related product monographs

Document Type Information Source  
 CYTOGAM Solution for infusion MPI, US: SPL/Old FDA, National Drug Code (US)
 CYTOTECT CP BIOTEST Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Hong Kong (HK)

Israel (IL)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.